Symptomatic slow acting drugs for osteoarthritis (SYSADOA)
Authors:
M.olejárová
Authors‘ workplace:
Revmatologický ústav Praha
Published in:
Geriatrie a Gerontologie 2013, 2, č. 1: 32-35
Category:
Review Article
Overview
SYSADOA inclu-ding glucosamine sulphate, chondroitin sulphate, diacerein, avocado-soy bean unsaponifiables (ASU), hyaluronate and its derivates, is a group of agents which improve the symptoms of osteoarthritis (OA), particularly pain and function, by a specific effect in the cartilage metabolism. They act slowly but its effect is long term lasting several weeks after the end of treatment. SYSADOA have neither serious side effects nor important drug interactions and so they are suitable also for the elderly polymorbid patients with concomitant pharmacotherapy. The efficacy of SYSADOA was proven in many clinical studies, but recently studies with negative results were reported, too. SYSADOA but currently still belong to therapeutical modalities recommended by international authorities as European League against Rheumatism (EULAR) or Osteoarthritis Research Society International (OARSI).
KEYWORDS:
SYSADOA – glucosamine sulphate – chondroitin sulphate – diacerein – avocado-soy bean unsaponifiables (ASU) – hyaluronate and its derivates – osteoarthritis – therapy
Sources
1. Jordan KM, Arden NK, Doherty M et al.: EULAR recommendations 2003: an evidence based approach to the management of the knee osteoarthritis: Report of a task force of the Standing Comittee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
2. Zhang W, Doherty M, Arden N et al.: EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Comittee for Internationl Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64: 669–81.
3. Zhang W, Doherty M, Leeb BF et al.: EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66(3): 377–88.
4. Zhang W, Moskowitz RW, Nuki G et al.: OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15(9): 981–1000.
5. Zhang W, Moskowitz RW, Nuki G et al.: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence–based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16(2): 137–62.
6. Zhang W, Nuki G, Moskowitz RW et al.: OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18(4): 476–99.
7. Hochberg MC, Altman RD, Toupin April K et al.: American College of Rheumatology 2012 Recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465–74.
8. Pavelka K. Doporučení České revmatologické společnosti pro terapii osteoartrózy. Čes Revmatol 2012; 20: 95–114.
9. Reginster JY, Deroisy R, Rovati LC et al.: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo–controlled clinical trial. Lancet 2001 Jan 27; 357: 251–6.
10. Pavelka K, Gatterová J, Olejárová M et al.: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–23.
11. Uebelhart D, Malaise M, Marcolongo R et al.: Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004; 12: 269–76.
12. Verbruggen G, Goemaere S, Veys EM: Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002; 21: 231–43.
13. Michel BA, Stucki G, Frey D et al.: Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005; 52: 779–86.
14. Rintelen B, Neumann K, Leeb BF: A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med 2006; 166: 1899–906.
15. Dougados M, Nguyen M, Berdah L et al.: ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 2001; 44: 2539–47.
16. Christensen P, Bartels EM, Astrup A et al.: Symptomatic efficacy of avocado-soybeans unsaponifiables (ASU) in OA patients: a metaanalysis of randomized, controlled trials. Osteoarthritis Cartilage 2008; 16(4): 399–408.
17. Lo GH, LaValley M, McAlindon T, Nelson DT: Intra–articular hyaluronic acid in the treatment of knee osteoarthritis. JAMA 2003; 290: 3115–21.
18. Wang CH, Lin J, Chang CH et al.: Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. J Bone Point Surg 2004; 86: 538–45.
19. Modawal A, Ferrer M, Choi HK, Castle JA: Hyaluronic acid injections relieve knee pain. J Fam Pract 2005; 54: 758–67.
20. Bellamy N, Campbell J, Robinson V et al.: Viscosuplementation for the treatment of osteoarthritis of the knee. The Cochrane Database of Systemic Reviews 2006, Issue 3. Art No.: CD005321.pub2. DOI 10.1002/14651858.CD005321.pub2
21. Clegg D: Effects of glucosamine, chondroitin sulfate and the two in combination in painful knee osteoarthritis. New Eng J Med 2006; 354: 795–807.
22. Wildi LM, Raynauld JP, Martel-Pelletier J et al.: Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011; 70(6): 982–9.
23. Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. Int J Rheum Dis 2012; 15(1): 69–77.
24. Strand V, Baraf HS, Lavin PT et al.: A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 2012; 20(5): 350–6.
25. Pavelka K, Uebelhart D: Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial®) vs hylan G–F20 (Synvisc®) in the treatment of symptomatic knee osteoarthritis. A double–blind, controlled, randomized, parallel-group non-inferiority study. Osteoarthritis Cartilage 2011; 19(11): 1294–300.
26. Navarro–Sarabia F, Coronel P, Collantes E et al.: AMELIA study group. A 40-month multicentre, randomised placebo–controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis 2011; 70(11): 1957–62.
27. DeGroot H 3rd, Uzunishvili S, Weir R et al.: Intra-articular injection of hyaluronic acid is not superior to saline solution injection for ankle arthritis: a randomized, double-blind, placebo-controlled study. J Bone Joint Surg Am 2012 Jan 4; 94(1): 2–8.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2013 Issue 1
Most read in this issue
- Symptomatic slow acting drugs for osteoarthritis (SYSADOA)
- Depression in old age and its treatment
- The „Short Physical Per-formance Battery“ and its use for evaluation of geriatric frailty in clinical practice
- The rational pharmacotherapy in older patients: the expert consensus 2012 on medications and treatments potentially inappropriate in the old age in Czech Republic